查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496003

吸藥輔助器市場 – 2024 年至 2029 年預測

Asthma Spacers Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

吸藥輔助器市場預計將以 4.84% 的複合年成長率成長，到 2029 年達到 2,698,043,000 美元。

吸藥輔助器是連接到氣喘藥物分配機（通常稱為吸入器）的容納室，以促進緩慢有效的藥物吸入。氣喘吸入器將藥物轉化為氣體形式並將其輸送到患者的肺部，從而打開氣道。然而，吸入器的口腔空間狹窄，迫使藥物進入氣道，導致難以吸入，甚至浪費。

儲霧器是一根長管，連接到吸入器上，允許患者緩慢吸入藥物，減少浪費並更好地吸入。由於污染加劇和慢性病數量增加，預計氣喘患者數量增加將在預測期內推動市場成長。氣喘病例數量的不斷增加，尤其是兒童，他們發現很難直接從吸入器中吸入，預計將推動市場需求。

市場促進因素：

  • 氣喘患者氣喘的增加，特別是兒童的增加，增加了氣喘吸入器和儲霧器的關注和市場引入。

由於需要專門護理、發病早、認知和氣喘治療的進步等因素，氣喘，尤其是兒童氣喘，越來越受歡迎。建議使用氣喘吸入器和儲霧器以確保適當的藥物輸送和治療效果。由於對氣喘症狀的認知提高和早期診斷，越來越多的人尋求醫療協助。氣喘管理和患者教育計劃的進步推動了這一趨勢。

氣喘是一種廣泛存在的慢性呼吸道疾病，會影響氣道，由於氣道狹窄和腫脹而導致呼吸困難。預計推動吸藥輔助器市場成長的主要原因之一是全球氣喘病例數量不斷增加，尤其是兒童。根據亞太過敏、氣喘和臨床免疫學協會（PACI）的資料，全球整體有超過30億人患有氣喘。

根據世界衛生組織（WHO）資料庫，2019 年有 461,000 人死於該疾病。由於家族遺傳和空氣污染加劇導致氣喘病例增加，預計將增加氣喘吸入器和儲霧器的採用，推動預測期內的市場成長。

  • 臨床對吸入療法的接受度不斷提高，推動了對吸藥輔助器的需求。

由於藥物傳輸增強、技術改進、副作用減少、兒科和老年患者易於使用以及吸入藥物的全身吸收減少，吸藥輔助器市場正在成長。這些設備幫助患者克服協調和時間安排方面的挑戰，從而獲得更好的臨床結果。它還可以減少口腔和喉嚨中的藥物沉積，從而最大限度地減少潛在的副作用。

Spacer 的使用者友善介面使這些人更容易獲得處方藥物並提高患者的依從性。墊片還可以減少全身吸收，並有助於將更高比例的藥物引導至肺部。它還可以增加肺部的藥物沉積並改善氣喘控制。病患教育和訓練計畫也在增加，支持使用墊片的臨床證據也在增加。

智慧吸入器技術與儲霧器的融合進一步增強了其吸引力。吸藥輔助器符合全球改善氣喘控制的努力，有助於市場成長。

市場限制因素

  • 用於降低整體藥物成本的無間隔技術的市場開拓正在限制吸藥輔助器市場的成長。

限制吸藥輔助器市場成長的是世界衛生組織建議使用自製替代品和無間隔物技術來降低藥物總成本。世衛組織的目標是根據其預防和控制非傳染性疾病全球行動計畫（2030）減少全世界的氣喘。

根據世界衛生組織的一項調查，只有五分之一的氣喘患者使用吸入器，大多數人不知道儲霧器的使用和重要性。世衛組織在其指導方針和宣傳計劃中提倡使用寶特瓶製作和使用自製墊片。自製間隔器的低廉價格，加上高昂的治療和藥物成本，鼓勵了DIY間隔器的採用，特別是在低收入國家，從而限制了前景廣闊的市場機會。

  • 不需要使用間隔器吸入的產品的成長可能會阻礙吸藥輔助器市場。

不需要吸入墊片的技術的開拓和新產品的推出對吸藥輔助器構成了重大的市場威脅。例如，梯瓦製藥公司已成功配製出一種無間隔物氣喘藥物，可改善患者的呼吸。 QVAR® RediHaler(TM) 是一項 FDA核准的無間隔技術，可像其前身一樣有效地輸送藥物。 QVAR(R) RediHaler(TM) 是圍繞呼吸驅動吸入器技術開發的，適合 4 歲以上的患者，甚至兒童也可以在沒有儲霧器的情況下使用。此類技術的興起預計將阻礙吸藥輔助器行業的市場。

主要進展

  • 2023 年 11 月 - Monaghan Medical Corporation 榮獲美國呼吸照護協會 (AARC) 頒發的 2023 年最高獎項。該獎項旨在表彰傑出的產品、友好的銷售人員、應對力、服務歷史、廣告的真實性以及對呼吸護理專業堅定不移的支持。該獎項在田納西州納許維爾舉行的 AARC 第 67 屆國際呼吸大會暨展覽會上頒發，表彰了 Monaghan Medical 對卓越呼吸護理的承諾。
  • 2023 年 3 月 - GSK plc 已接受 Nucala（美泊利單抗）的新藥認證申請，作為嚴重嗜酸性粒細胞氣喘(SEA) 的附加維持治療。如果核准，Nucala將成為中國首個針對成人和青少年SEA患者的拮抗介白素-5（IL-5）標靶治療。本申請基於中國患者的 III 期臨床試驗和全球 SEA 開發計劃的積極資料。中國氣喘的成人人數估計為4600萬，其中6%患有嚴重氣喘。 Nucala 目前在中國核准用於治療嗜酸性粒細胞肉芽腫性多血管炎成人患者。

主要市場區隔

依產品類型

  • AeroChamber
  • OpticChamber
  • Easivent
  • 其他

按分銷管道

  • 線上
  • 離線

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 其他
  • 中東/非洲 阿拉伯聯合大公國 沙烏地阿拉伯 其他中東/非洲
  • UAE
  • 沙烏地阿拉伯
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章吸藥輔助器市場：依產品類型

  • 介紹
  • 航空室
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 視室
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 容易發洩
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章吸藥輔助器市場：依通路

  • 介紹
  • 線上
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 離線
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章吸藥輔助器市場：依地區

  • 介紹
  • 北美洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 南美洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 歐洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 中東/非洲
    • 依產品類型
    • 按分銷管道
    • 按國家/地區
  • 亞太地區
    • 依產品類型
    • 按分銷管道
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競賽儀表板

第9章 公司簡介

  • Zydus Cadila
  • Pari Gmbh
  • Cipla
  • Glaxo SmithKline Pharmaceuticals Ltd
  • Rossmax International Ltd.
  • Lupin
簡介目錄
Product Code: KSI061611950

The asthma spacers market is expected to reach a value of US$2,698.043 million by 2029, growing at a CAGR of 4.84% It was valued at US$1,937.567 million in 2022.

An asthma spacer is a holding chamber attached to an asthma medicine dispensing machine, commonly known as an inhaler, facilitating slower and more effective inhalation of the medicine. An asthma inhaler converts the medicine into gas form and delivers it to the patient's lungs, opening the airways. However, the inhaler has less mouth space and rushes the medicine into the person's airways, making it hard to inhale the medicine and even leading to wastage.

A spacer is attached to the inhaler, a long tube that enables patients to slowly inhale the medicine, reducing wastage and enabling better inhalation. Increasing cases of asthma owing to the rise in pollution and growing cases of chronic diseases are expected to drive the market growth during the forecasted period. Rising cases of asthma, especially among children, are expected to drive the market demand since children find it difficult to inhale through the inhaler directly.

Market Drivers:

  • Growing cases of asthma, especially among children, have raised concerns and increased market adoption of asthma inhalers and spacers.

Asthma, particularly among children, is gaining popularity due to factors such as the need for specialized care, early onset, awareness, and advancements in asthma management. Asthma inhalers and spacers are recommended to ensure proper medication delivery and treatment efficacy. The growing awareness of asthma symptoms and early diagnosis has led to more individuals seeking medical attention. Advancements in asthma management and patient education programs are contributing factors to this trend.

Asthma is a widely prevalent respiratory chronic disease that affects the airways, making it difficult for the person to breathe owing to narrowed and/ or swollen up airways. One of the prime reasons expected to drive the asthma spacers market growth is the increasing cases of asthma worldwide, especially among children. Data from the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (PACI) shows that globally, more than 3 billion people suffer from asthma.

The World Health Organization (WHO) database shows that 461,000 people died because of this disease in 2019. Increasing cases of asthma owing to family genetics and rising air pollution are expected to increase the adoption of asthma inhalers and spacers, driving the market growth during the forecast period.

  • Increasing clinical acceptance of inhaled therapies is driving up demand for asthma spacers.

The asthma spacers market is growing due to the enhanced medication delivery, improved technique, reduced side effects, ease of use for children and elderly patients, and reduced systemic absorption of inhaled medications. These devices help patients overcome challenges related to coordination and timing, leading to better clinical outcomes. They also help reduce the deposition of medication in the mouth and throat, minimizing potential side effects.

The user-friendly interface of spacers makes it easier for these populations to receive their prescribed medications, improving patient compliance. Spacers also help reduce systemic absorption, directing a higher proportion of the drug to the lungs. They also increase medication deposition in the lungs, enhancing asthma control. Patient education and training programs are also growing, and clinical evidence supporting spacer use is growing.

The integration of smart inhaler technologies with spacers further enhances their appeal. Asthma spacers align with global efforts for better asthma control, contributing to market growth.

Market Restraints

  • The development of spacer-free technology to reduce the overall cost of medication constraints the market growth of asthma spacers.

The WHO recommends using homemade replacements and spacer-free technology to lower the overall cost of medication, which is what is limiting the market growth of asthma spacers. The WHO aims to reduce global asthma under its Global Action Plan for the Prevention and Control of NCDs, 2030.

A study by the organization observed that only 1/5th of patients suffering from asthma have access to inhalers, and the majority were not aware of the usage and importance of spacers. In its guidelines and awareness programs, WHO promoted the making and usage of homemade spacers using plastic bottles, which could be substituted for branded asthma spacers. The low cost of homemade spacers, accompanied by high treatment and medication costs, encourages the adoption of DIY spacers, especially in low-income countries, and hence constraints the prospective opportunity for the market.

  • Growth of products that do not need to be inhaled with spacers could hinder the asthma spacers market.

The development of technology and the launch of new products that do not require a spacer for inhalation pose a significant market threat for asthma spacers. Teva Pharmaceuticals. for instance, has successfully formulated spacer-free asthma medication, which enables better breathing for the patients. QVAR(R) RediHaler(TM) is an FDA-approved spacer-free technology that delivers medication as effectively as its predecessor. QVAR(R) RediHaler(TM) has been developed around breath-actuated inhaler technology and is apt for four-year-old and older patients, which can be used without the spacer, even for children. The rise in such technology is expected to hinder the market for the asthma spacer industry.

Key Developments:

  • November 2023- Monaghan Medical Corporation was awarded the 2023 Zenith Award by the American Association for Respiratory Care (AARC). The award is prestigious for its exceptional products, accessible sales staff, responsiveness, service record, truth in advertising, and unwavering support of the respiratory care profession. The award was presented at the AARC's 67th International Respiratory Convention & Exhibition in Nashville, Tennessee, highlighting Monaghan Medical's commitment to excellence in respiratory care.
  • March 2023- GSK plc accepted a new drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma (SEA). If approved, Nucala would be the first targeted anti-interleukin-5 (IL-5) treatment in China for adult and adolescent patients with SEA. The application is based on positive data from a phase III trial among Chinese patients and the global SEA development program. Asthma affects an estimated 46 million adults in China, with 6% experiencing severe asthma. Nucala is currently approved in China for adults with eosinophilic granulomatosis with polyangiitis.

Key Market Segments

By Product Type

  • AeroChamber
  • OpticChamber
  • Easivent
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.1. Analyst View

5. ASTHMA SPACERS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. AeroChamber
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. OpticChamber
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Easivent
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. ASTHMA SPACERS MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Online
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Offline
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness

7. ASTHMA SPACERS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product Type
    • 7.3.2. By Distribution Channel
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product Type
    • 7.4.2. By Distribution Channel
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. Spain
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. France
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Others
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product Type
    • 7.5.2. By Distribution Channel
    • 7.5.3. By Country
      • 7.5.3.1. UAE
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. Saudi Arabia
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. Others
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product Type
    • 7.6.2. By Distribution Channel
    • 7.6.3. By Country
      • 7.6.3.1. Japan
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. China
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. South Korea
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Taiwan
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Thailand
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Indonesia
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Zydus Cadila
  • 9.2. Pari Gmbh
  • 9.3. Cipla
  • 9.4. Glaxo SmithKline Pharmaceuticals Ltd
  • 9.5. Rossmax International Ltd.
  • 9.6. Lupin